Outpatient treatment and quality of life of patients with interstitial cystitis and Hunner’s lesion: cohort cross-sectional study

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Aim. To assess the quality of life of patients with interstitial cystitis (IC) and to study effective options used to control symptoms on outpatient basis.

Materials and methods. The results of a descriptive prospective cross-sectional cohort study are presented. The medical charts of patients who were treated in the City Clinical Hospital named after Spasokukotsky from 2021 to 2023 were analyzed. Eighty inpatient medical charts of various patients with a final diagnosis of IC with Hunner's lesion were identified. Only 53 patients were interviewed due to the inclusion/exclusion criteria. Respondents were asked to complete a survey consisting of 15 questions. The survey was carried out online for patients who did not require surgical treatment at the time of the study, and offline for patients admitted for repeated surgical treatment.

Results. The average age of respondents was 59.0±11.1 years. 58% (31) of patients noted the presence of constant pain in the pelvic area during the day, while 85% (45) of patients reported pain outside the bladder area, in the urethra and perineum. The intensity of pain in the pelvic area was 4.9 (2.3-5.6) points. Higher pain scores 6.24 (5.8-9.0) were observed in 47% (25) of patients admitted for repeat surgical treatment. 62% (33) of patients had a titer of bacteria in a urine test above 104, while 51% (27) of patients experienced relief of symptoms after taking antibacterial drugs. For the treatment and symptomatic relief, the following are most often used: pentosan sodium polysulfate (26%, n=14), antibacterial drugs of the nitrofuran group (25%, n=13), amitriptyline (15%, n=8), non-steroidal anti-inflammatory drugs (11%, n=6) patients. 23% (12) of respondents received intravesical therapy. The time from the onset of symptoms to the final diagnosis was 48 (24-96) months.

Conclusions. Although infection is a criterion for excluding the diagnosis of IC, more than 62% of patients have positive urine culture. The results obtained indicate the need to improve existing approaches to the diagnosis of IC, as well as to develop treatment algorithms for painful bladder syndrome to control symptoms.

Texto integral

Acesso é fechado

Sobre autores

A. Karasev

FGBOU VO “Russian University of Medicine”

Email: alex-10k@mail.ru

Ph.D. student of the Department of Urology 

Rússia, Moscow

T. Bresso

Pirogov Russian National Research University

Email: bresso54@mail.ru

Candidate of Psychological Sciences

Rússia, Moscow

O. Markova

FGBOU VO “Russian University of Medicine”

Autor responsável pela correspondência
Email: o.d.markova@mail.ru

urologist of the State Medical University named after S.P. Botkin DZM

Rússia, Moscow

G. Kasyan

FGBOU VO “Russian University of Medicine”; Municipal Clinical Hospital named after S.I. Spasokukotskiy, Moscow Health Department

Email: g.kasyan@outlook.com

Ph.D., MD, professor at the Department of Urology of FGBOU VO “Russian University of Medicine”

Rússia, Moscow; Moscow

D. Pushkar

FGBOU VO “Russian University of Medicine”; Municipal Clinical Hospital named after S.I. Spasokukotskiy, Moscow Health Department

Email: Pushkardm@mail.ru

Academician of RAS, Ph.D., MD, Professor, Head of the Department of Urology of FGBOU VO “Russian University of Medicine”, Honored Doctor of the Russian Federation, Honored Scientist of the Russian Federation, Chief Urologist of the Ministry of Health of the Russian Federation

Rússia, Moscow; Moscow

Bibliografia

  1. Loran O.B., Sinyakova L.A., Mitrokhin A.A., Plesovskikh A.M., Steinberg M.L., Vinarova N.A. Modern view on the problem of interstitial cystitis. MS. 2011. № 11–12. Russian (Лоран О.Б., Синякова Л.А., Митрохин А.А., Плесовский А.М., Штейнберг М.Л., Винарова Н.А. Современный взгляд на проблему интерстициального цистита. МС. 2011. № 11–12).
  2. Clemens J.Q., Meenan R.T., Rosetti M.C., Gao S.Y., Calhoun E.A. Prevalence and incidence of interstitial cystitis in a managed care population. J Urol. 2005 Jan;173(1):98–102.
  3. Clemens J.Q., Erickson D.R., Varela N.P., Lai H.H. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2022;208(1):34–42.
  4. Sultanova E.A. Interstitial cystitis: some aspects of diagnosis and treatment. RMG.2010;29:1798. Russian (Султанова Е.А. Интерстициальный цистит: некоторые аспекты диагностики и лечения. РМЖ.2010; 29:1798).
  5. Parsons C.L. How does interstitial cystitis begin? Transl Androl Urol. 2015 Dec;4(6):605–610.
  6. Yu W.R., Jhang J.F., Chen B.Y., Ou S.R., Li H.M., & Kuo H.C. (2022). Multimodal Treatment with Cognitive Behavioral Therapeutic Intervention Plus Bladder Treatment Is More Effective than Monotherapy for Patients with Interstitial Cystitis/Bladder Pain Syndrome-A Randomized Clinical Trial. Journal of clinical medicine, 11(20), 6221.
  7. Pushkar D.Yu., Zaitsev A.V., Kovylina M. V., Tsybulya O.A., Vasiliev A.O. Histomorphology of the urothelium in inflammatory diseases of the bladder. Bulletin of VolSMU. 2011. No. 2(38). Russian (Пушкарь Д.Ю., Зайцев А.В., Ковылина М.В., Цыбуля О.А., Васильев А.О. Гистоморфология уротелия при воспалительных заболеваниях мочевого пузыря. Вестник ВолГМУ. 2011; 2:94–97).
  8. Kasyan G., Kupriyanov Y., Karasev A., Baibarin K., Pushkar D. Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double-blind, placebo-controlled, randomized study. Cent European J Urol. 2021;74(2):201–207.
  9. Grigoryan B., Kasyan G., Pivazyan L., Pushkar D. Pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis with Hunner’s lesions or glomerulations: systematic review and meta-analysis. Ther Adv Urol. 2022 Jun 2;14:17562872221102809.
  10. Bade J.J., Laseur M., Nieuwenburg A., van der Weele L.T., Mensink H.J. A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis. Br J Urol. 1997 Feb;79(2):168–171.
  11. Barua J.M., Arance I., Angulo J.C., Riedl C.R. A systematic review and meta-analysis on the efficacy of intravesical therapy for bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2016 Aug;27(8):1137–147.
  12. Jiang Y.H., Jhang J.F., Lin T.Y., Ho H.C., Hsu Y.H., Kuo H.C. Therapeutic Efficacy of Intravesical Platelet-Rich Plasma Injections for Interstitial Cystitis/Bladder Pain Syndrome-A Comparative Study of Different Injection Number, Additives and Concentrations. Front Pharmacol. 2022 Mar 22;13:853776.
  13. Khamedov R.G., Gorgotsky I.A., Shkarupa A.G., Shkarupa D.D., Gadzhiev N.K. Platelet-rich plasma: application for interstitial cystitis and erectile dysfunction. Urology Herald. 2022;10(1):121–127. Russian (Хамедов Р.Г., Горгоцкий И.А., Шкарупа А.Г., Шкарупа Д.Д., Гаджиев Н.К. Использование обогащённой тромбоцитами плазмы при интерстициальном цистите и эректильной дисфункции. Вестник урологии. 2022;10(1):121–127).
  14. Jhang JF, Wu SY, Lin TY, Kuo HC. Repeated intravesical injections of platelet-rich plasma are effective in the treatment of interstitial cystitis: a case control pilot study. Low Urin Tract Symptoms. 2019 Apr;11(2): 42–47.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
2. Fig. 1. Inclusion/exclusion criteria

Baixar (194KB)
3. Fig. 2. Study design

Baixar (126KB)
4. Fig. 3. Pain intensity according to VAS

Baixar (46KB)
5. Fig. 4. Most used medications for treatment/symptom relief by frequency of use

Baixar (30KB)
6. Fig. 5. Features of the pain symptom

Baixar (101KB)

Declaração de direitos autorais © Bionika Media, 2024

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies